Paul R. Taskier’s professional practice consists of large, multiparty civil litigation in federal and state courts across the nation and international arbitration. For more than 25 years, his practice has encompassed cases in such diverse areas as antitrust, insurance coverage, international arbitration, defamation, intellectual property, and licensing disputes, as well as major commercial disputes and contract actions, and related appellate litigation. He has represented Tyson Foods and others in multidistrict antitrust litigation, Novell, Inc. against Microsoft in In Re Microsoft Antitrust Litigation, and Arthur Andersen LLP, McDonald’s Corporation, Ogden Corporation, Oracle Corporation and Pfizer Inc in major insurance coverage litigation or arbitration. Recently, in federal court in Marshall, Texas, he led the firm's trial team against Johnson & Johnson over infringement of his client's patent by J&J's Cypher drug-eluting cardiac stent. The jury returned a $482 million verdict, later increased to a $593 million judgment, the largest US patent judgment in 2011, and the largest verdict for an individual plaintiff in the country. As a result, American Lawyer Litigation Daily named him "Litigator of the Week" for Feb. 3, 2011. He was also named by Lawyers USA as one of five "Lawyers of the Year" for 2011. He is a "Litgation Star" for Benchmark Plaintiffs Guides for 2012 and 2013, and was named one of the "500 Leading Lawyers in America" in the "Lawdragon 500" for 2011 and 2012. In 2008, he led the damages case as one of two Dickstein trial counsel in Saffran v. Boston Scientific Corporation, a case alleging patent infringement by the Taxus drug-eluting cardiac stent, which returned a judgment of over $500 million for the firm's client, the third largest damages award in the United States in 2008 and the fifth largest patent damages award in U.S. history. His practice also encompasses representation of foreign entities and individuals in the U.S. courts.